This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover
with randomized withdrawal study in Type 1 diabetes and celiac disease subjects attempting a
GFD for at least one year prior to screening.
Phase:
Phase 2
Details
Lead Sponsor:
Immunogenics, LLC
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)